1） 厚生労働省ホームページ：食中毒統計資料 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/syokuchu/04.html
2） Codex Alimentarius: Code of Practice, General Principles of Food Hygiene. CAC/RCP 1-1969
3） Codex Alimentarius: General Standard for the Labelling of Prepacked Foods. CODEX STAN1-1985
4） 平成27年3月30日消食表第139号消費者庁次長通知食品表示基準について．別添アレルゲンを含む食品に関する表示．
5） 令和元年9月19日消食表第322号消費者庁次長通知アレルゲンを含む食品の表示について．
6） 平成27年3月30日消食表第139号消費者庁次長通知食品表示基準について．別添アレルゲンを含む食品の検査方法．
7） 赤城智美：食物アレルギーを取り巻く現状．食品衛生研究，67，15-24（2017）
8） 温泉川肇彦：食物アレルギーと食品アレルゲン管理について．食品衛生研究，69，17-30（2019）
9） 清田恭平，藤原有佳，足立和人，亀田誠，阿久津和彦，梶村計志：乳清分が非意図的に混入した学校給食パンによる乳アレルギー発症事例における混入経路の検証．アレルギー，63，787-793（2014）
10） 日本小児アレルギー学会食物アレルギー委員会：食物アレルギー診療ガイドライン2016．共和企画，東京．2016．
11） 今井孝成，杉崎千鶴子，海老澤元宏：消費者庁「食物アレルギーに関連する食品表示に関する調査研究事業」平成23年即時型食物アレルギー全国モニタリング調査結果報告．アレルギー，65，942-946（2016）
12） Rona R. J., Keil T., Summers C., Gislason D., Zuidmmer L., Sodergren E., Sigurdardottir S. T., Lindner T., Goldhahn K., Dahlstrom J., McBride D. and Madsen C.: The prevalence of food allergy: A meta-analysis. J Allergy Clin Immunol, 120, 638- 646 (2007)
13） Chafen J. J. S., Newberry S. J., Riedl M. A., Bravata D. M., Maglione M., Suttorp M. J., Sundaram V., Paige N. M., Towfige A., Hulley B. J. and Shekelle P. G.: Diagnosing and managing common food allergies. A systematic review. JAMA, 303, 1848-1856 (2010)
14） Ebisawa M. and Sugizaki C.: Prevalence of pediatric allergic diseases in the first 5 years of life. J Allergy Clin Immunol, 121, S237 (2008)
15） 日本学校保健会：平成25年度学校生活における健康管理に関する調査事業報告書．2014．
16） 日本学校保健会：平成26年度児童生徒の健康状態サーベイランス事業報告書．2016．
17） Ebisawa M., Ikematsu K., Imai T. and Tachimoto H.: Food allergy in Japan. Allergy Clin Immunol Int, 15, 214-217 (2003)
18） 川瀬興三，御子神隆：酵素免疫測定法（ELISA）抑制試験を用いたアレルギー用ミルク，ウシカゼインとその酵素分解産物の抗原性の検討．東邦医学会雑誌，35，509-561（1989）
19） Ena J. M., Beresteijn E. C. H. V., Robben A. J. P. M. and Schmidt D. G.: Whey protein antigenicity reduction by fugal proteinases and a pepsin/pancreatin combination. J Food Sci, 60, 104-116 (1995)
20） Esteban M. M., Ara M. C. G., Molas M. B., Martinez M. T. B., Muñoz F. M. and Pena J. M. D., Evaluation of an extensively hydrolyzed casein-whey protein formula in cow’s milk protein hypersensitivity. J Pediatr Gastrenterol Nutr, 26, 398-401 (1998)
21） Muraro A., Hoekstra M. O., Meijer Y., Lifschitz C., Wampler J. L., Harris C. and Scalabrin D. M. F.: Extensively htdrolysed casein formula supplemented with Lactobacillus rhamnosus GG maintains hypoallergenic status: randomized double- blind, placebo-controlled crossover trial. BMJ Open, 2, e000637 (2012)
22） Docena G., Rozenfeld P., Fernández and Fossati C. A.: Evaluation of the residual antigenicity and allergenicity of cow’s milk substitutes by in vitro tests. Allergy, 57, 83-91 (2002)
23） Cordle C. T., Mahmoud M. I. and Moore V.: Immunogenicity evaluation of protein hydrolysates for hypoallergenic infant formulae. J Pediatr Gastroenterol Nutr, 13, 270276 (1991)
24） Boner A. L., Benedetti M., Spezia E., Piacentini G. L. and Bellanti J. A.: Evaluation of the allergenicity of infant formulas in a guinea pig model. Ann Allergy, 68, 404-406 (1992)
25） COMMISSION DIRECTIVE 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC
26） Halken S., Høst A., Hansen L. G. and Østerballe O.: Safety of a new, ultrafiltrated whey hydrolysate formula in children with cow milk allergy: a clinical investigation. Pediatr Allergy Immunol, 4, 53-59 (1993)
27） American Academy of Pediatrics Committee on Nutrition: Hypoallergenic infant formulas. Pediatrics, 106, 346-349 (2000)
28） Vandenplas Y., Hausr B., Van den Borre C., Clybouw C., Mahler T., Hachimi-Idrissi S., Deraeve L., Malfroot A. and Dab I.: The long-term effect of partial whey hydrolysate formula on the prophylaxis of atopic disease. Eur J Pediatr, 154, 488-494 (1995)
29） Exl B. M., Deland U., Secretin M. C., Preysch U., Wall M. and Shmerling D. H.: Improved general health status in an unselected infant population following an allergen-reduced dietary intervention programme: the ZUFF-STUDY-PROGRAMME. Part II: infant growth and health status to age 6 months. Eur J Nutr, 39, 145-156 (2000)
30） Berg A. V., Filipiak-Pittroff B., Krämer U., Hoffmann B., Link E., Beckmann C., Hoffmann U., Reinhardt D., Grübl A., Heinrich J., Wichmann H. E., Bauer C. P., Koletzko S. and Berdel D.: Allergies in high-risk schoolchildren after early intervention with cow’s milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol, 131, 1565-1573 (2013)
31） Szajewska H. and Horvath A.: A partially hydrolyzed 100% whey formula and risk of eczema and allergy: an updated meta-analysis. WAO Journal, 10, 27-37 (2017)
32） Boyle R., Ierodiakonou D., Khan T., Chivinge J., Robinson Z., Geoghegan N., Jarrold K., Afxentiou T., Reeves T., Cunha S., Trivella M., Garcia-Larsen V. and Leonardi-Bee J.: Hydrolysed formula and risk of allergic or autoimmune disease: systematic review and meta-analysis. BMJ, 352, i974 (2016)
33） Kido J., Nishi N., Sakaguchi M. and Matsumoto T.: Most cases of cow’s milk allergy are able to ingest a partially hydrolyzed formula. Ann Allergy Asthma Immunol, 115, 330- 331 (2015)
34） Inuo C., Tanaka K., Nakajima Y., Yamakawa K., Matsubara T., Iwamoto H., Tsuge I., Urisu A, and Kondo Y.: Tolerability of partially and extensively hydrolysed milk formulas in children with cow’s milk allergy. Asia Pac J Clin Nutr, 28, 49-56 (2019)
35） 犬尾千聡，伊藤直香，高増哲也，栗原和幸：牛乳経口耐性誘導療法の1例．小児科臨床，63，999-1003（2010）
36） Inuo C., Tanaka K., Suzuki S., Nakajima Y., Yamakawa K., Tsuge I., Uris A. and Kondo Y.: Oral immunotherapy using partially hydrolyzed formula for cow’s milk protein allergy: a randomized, controlled trial. Int Arch Allergy Immunol, 177, 259-268 (2018)
37） Isolauri E., Sütas Y., Salo M. K., Isosomppi R. and Kaila M.: Elimination diet in cow’s milk allergy: risk for impaired growth in young children. J Pediatr, 132, 1004-1009 (1998)
38） 長谷川実穂，今井孝成，林典子，柳田紀之，小俣貴嗣，佐藤さくら，富川盛光，宿谷明紀，海老澤元宏：不適切な食物除去が食物アレルギー患者と保護者に与える影響．日本小児アレルギー学会誌，25，163-173（2011）
39） 小俣貴嗣，宿谷明紀，今井孝成，田知本寛，海老澤元宏：ブラインド法乾燥食品粉末食物負荷試験に関する検討（第 1 報）－非加熱全卵・卵黄負荷試験－．アレルギー，58，524⁻536（2009）
40） 小俣貴嗣，宿谷明紀，今井孝成，田知本寛，海老澤元宏：ブラインド法乾燥食品粉末食物負荷試験に関する検討（第2報）－牛乳負荷試験－．アレルギー，58，779⁻789（2009）
41） Ohtani K., Sato S., Sykuya A., Asaumi T., Ogura K., Koike Y., Iikura K., Yanagida N., Imai T. and Ebisawa M.: Natural history of immediate-type hen’s egg allergy in Japanese children. Allergol Int, 65, 153-157 (2016)
42） Sato S., Ogura K., Takahashi K., Sato Y., Yanagida N. and Ebisawa M.: Usefulness of antigen-specific IgE probability curves derived from the 3gallergy assay in diagnosing egg, cow’s milk, and wheat allergies. Allergol Int, 66, 296-301 (2017)
43） 佐藤さくら，海老澤元宏：末梢血好塩基球を用いた食物アレルギーの診断．小児科臨床，63，2489-2496（2010）
44） Hemmings O., Kwok M., McKendry R. and Santos A. F.: Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep, 18, 77-89 (2018)
45） Sato S., Tachimoto H., Shukuya A., Kurosaka N., Yanagida N., Utsunomiya T., Iguchi M., Komata T., Imai T., Tomikawa M. and Ebisawa M.: Basophil activation marker CD203c is useful in the diagnosis of hen’s egg and cow’s milk allergies in children. Int Arch Allergy Immunol, 152, 54-61 (2010)
46） Rubio A., Vivinus-Nébot M., Bourrier T., Saggio B., Albertini M. and Bernard A.: Benefit of the basophil activation test in deciding when to reintroduce cow’s milk in allergic children. Allergy, 66, 92-100 (2011)
47） Hoffmann H. J., Santos A. F., Mayorga C., Nopp A., Eberlein B., Ferrer M., Rouzaire P., Ebo D. G., Sabato V., Sanz M. L., Pecaric-Petkovic T., Patil S. U., Hausmann O. V., Shreffler W. G., Korosec P. and Knol E. F.: The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy, 70, 1393-1405 (2015)
48） Wanich N., Nowak-Wegrzyn A., Sampson H. A. and Shreffler W. G.: Allergen-specific basophil suppression associated with clinical tolerance in patients with milk allergy. J Allergy Clin Immunol, 123, 789-794 (2009)
49） Nucera E., Pecora V., Buonomo A., Rizzi A., Aruanno A., Pascolini L., Ricci A. G., Rienzo A. D., Mezzacappa S., Ferraironi M., Patriarca G., Gasbarrini G. and Schiavino D.: Utility of basophil activation test for monitoring the acquisition of clinical tolerance after oral desensitization to cow’s milk: pilot study. United Eur Gastroenterol J, 3, 272- 276 (2015)
50） Nilsson C., Nordvall L., Johansson S. G. O. and Nopp A.: Successful management of severe cow’s milk allergy with omalizumab treatment and CD-sens monitoring. Asia Pac Allergy, 4, 257-260 (2014)
51） McLaughlan P., Anderson K. J. and Coombs R. R. A.: An oral screening procedure to determine the sensitizing capacity of infant feeding formulae. Clin Allergy, 11, 311-318 (1981)
52） Piacentini G. L., Bertolini E., Spezia E., Piscione T. and Boner A. L.: Ability of new infant formula prepared from partially hydrolyzed bovine whey to induce anaphylactic sensitization: evaluation in a guinea pig model. Allergy, 49, 361-364 (1994)
53） Hennersdorf F., Florian S., Jakob A., Baumgärtner K., Sonneck K., Nordhein A., Bifdermann T., Valent P. and Bühring H.J.: Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Research, 15, 325-335 (2005)
54） MacGlashan D. W.: Basophil activation testing. J Allergy Clin Immunol, 132, 777-787 (2013)
55） Torrero M. N., Larson D., Hübner M. P. and Mitre E.: CD200R surface expression as a marker of murine basophil activation. Clin Exp Allergy, 39, 361-369 (2009) Bakocevic N., Claser C., Yoshikawa S., Jones L. A., Chew S., Goh C. C., Malleret B., Larbi A., Ginhoux F., Lafaille M. C. D., Karasuyama H., Renia L. and Ng L. G.: CD41 is a reliable identification and activation marker for murine basophils in the steady state and during helminth and malarial infections. Eur J Immunol, 44, 1823-1834 (2014)
56） Gorczynski R., Chen Z., Kai Y., Lee L., Wong S. and Marsden P. A.: CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol, 172, 7744-7749 (2004)
57） Hoek R. M., Ruuls S. R., Murphy C. A., Wright G. J., Goddard R., Zurawski S. M., Blom B., Homola M. E., Streit W. J., Brown M. H., Barclay A. N. and Sedgwick J. D.: Down- regulation of the macrophage lineage through interaction with OX2 (CD200). Science, 290, 1768-1771 (2000)
58） Zhang S., Cherwinski H., Sedgwick J. D. and Phillips J. H.: Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol, 173, 6786-6793 (2004)
59） Kojima T., Obata K., Mukai K., Sato S., Takai T., Minegishi Y. and Karasuyama H.: Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner. J Immunol, 179, 7093-7100 (2007)
60） Nimmerjahn F. and Ravetch J. V.: Fcgamma receptors as regulators of immune responses. Nat Rev Immunol, 8, 34-47 (2008)
61） Yoshida S.: Isolation of β-Lactoglobulin and α-Lactalbumin by gel filtration using Sephacryl S-200 and purification by diethylaminoethyl ion-exchange chromatography. J Dairy Sci, 73, 2292-2298 (1990)
62） Obata K., Mukai K., Tsujimura Y., Ishiwata K., Kawano Y., Minegishi Y., Watanabe N. and Karasuyama H.: Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood, 110, 913-920 (2007)
63） Ommen R. V., Vredendaal A. E. C. M., Gooyer M. D., Oudenaren A. V. and Savelkoul H. F. J.: The effect of IFN-y, alum and complete Freund adjuvant on TNP-KLH induced IgG1, IgE and IgG2a responses in mice. Mediators Inflamm, 3, 387-392 (1994)
64） Khodoun, M. V., Kucuk Z. Y., Strait R.T., Krishnamurthy D., Janek K., Clay C. D., Morris S. C. and Finkelman F. D.: Rapid desensitization of mice with anti- FcgRIIb/FcgRIII mAb safely prevents IgG-mediated anaphylaxis. J. Allergy Clin. Immunol, 132, 1375-1387 (2013)
65） Matsuoka K., Shitara H., Taya C., Kohno K., Kikkawa Y. and Yonekawa H.: Novel basophil- or eosinophil-depleted mouse models for functional analyses of allergic inflammation. PLoS ONE, 8, e60958 (2013)
66） Lei H. Y., Lee S. H. and S. H. Leir S. H.: Antigen-induced anaphylactic death in mice. Int Arch Allergy Immunol, 109, 407-412 (1996)
67） Miyajima I., Dombrowicz D., Martin T. R, Ravetch J. V., Kinet J. P. and Galli S. J.: Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcgRIII. J Clin Invest, 99, 901-914 (1997)
68） Finkelman F. D.: Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol, 120, 506-515 (2007)
69） Tsujimura Y., Obata K., Mukai K., Shindou H., Yoshida M., Nishikado H., Kawano Y., Minegishi Y., Shimizu T. and Karasuyama H.: Basophils play a pivotal role in immuneoglobulin-G-mediated but not immunoglobulin-Emediated systemic anaphylaxis. Immunity, 28, 581-589 (2008)
70） Mukai K., Obata K., Tsujimura Y. and Karasuyama H.: New insights into the roles for basophils in acute and chronic allergy. Allergol Int, 58, 11-19 (2009)
71） Mancardi D. A., Iannascoli B., Hoos S., England P., Daëron M. and Bruhns P.: FcyRIV is a mouse IgE receptor that resembles macrophage FcsRI in humans and promotes IgEinduced lung inflammation. J Clin Invest, 118, 3738-3750 (2008)
72） Jönsson F., Mancardi D. A., Kita Y., Karasuyama H., Iannascoli B, Rooijen N. V., Shimizu T., Daëron M. and Bruhns P.: Mouse and human neutrophils induce anaphylaxis. J Clin Invest, 121, 1484-1496 (2011)
73） Jiao D., Liu Y., Lu X., Pan Q., Zheng J., Liu B., Liu Y., Wang Y. and Fu N.: Characteristics of anaphylaxis inducing IgG immune complexes triggering murine passive systemic anaphylaxis. Allergy, 68, 236-245 (2013)
74） Wright G. J., Cherwinski H., Foster-Cuevas M., Brooke G., Puklavec M. J., Bigler M., Song Y., Jenmalm M., Gorman T. McClanahan T., Liu M. R., Brown M. H., Sedgwick J. D., Phillips J. H. and Barclay A.: Characterization of the CD200 receptor family in mice and human and their interactions with CD200. J Immunol, 171, 3034-3046 (2003)
75） Voehringer D., Rosen D. B., Lanier L. L. and Loeksler R. M.: CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. J Biol Chem, 52, 54117-54123 (2004)
76） Sicherer S. H., Noone S. A., Koerner C. B., Christie L., Burks A. W. and Sampson H. A.: Hypoallergenicity and efficacy of an amino acid-based formula in children with cow’s milk and multiple food hypersensitivities. J Pediatr, 138, 688-693 (2001)
77） American Academy of Pediatrics Committee on Nutrition: Soy protein-based formulas: recommendation for Use in infant feeding. Pediatrics, 101, 148-153
78） Fiocchi A., Restani P., Lucarelli S., Lombardi G., Magazzù G., Marseglia G. L., Pittschieler K., Tripodi S., Troncone R. and Ranzini C.: A hydrolysed rice-based formula is tolerated by children with cow’s milk allergy: a multi-centre study. Clin Exp Allergy, 36, 311-316 (2006)
79） 令和元年9月9日消食表第296号消費者庁次長通知「特別用途食品の表示許可等について」の全部改正について．
80） Mckenzie H. A.: Whole casein: isolation, properties, and zone electrophoresis, in “Milk Proteins Chemistry and Molecular Biology Vol.II”, edited by Mckenzie H. A., Academic Press, New York and London, pages 87-116 (1971)
81） Lack G.: Epidemiologic risks for food allergy. J Allergy Clin Immunol, 121, 1331-1336 (2013)
82） Natsume O. and Ohya Y.: Recent advancement to prevent the development of allergy and allergic diseases and therapeutic strategy in the perspective of barrier dysfunction. Allergol Int, 67, 24-31 (2018)
83） Katz Y., Rajuan N., Goldberg M. R., Eisenberg E., Heyman E., Cohen A. and Leshno M.: Early exposure to cow’s milk protein is protective against IgE-mediated cow’s milk protein allergy. J Allergy Clin Immunol, 126, 77-82 (2010)
84） Koplin J.J., Osborn N. J., Wake M., Martin P. E., Gurrin L. C., Robinson M. N., Tey D., Slaa M., Thiele L., Miles L., Anderson D., Tan T., Dang T. D., Hill D. J., Lowe A. J., Matheson M. C., Ponsonby A. L., Tang M. L. K., Dharmage S. C. and Allen K. J.: Can early introduction of egg prevent egg allergy in infants? A population-based study. J Allergy Clin Immunol, 126, 807-813 (2010)
85） Du Toit G., Roberts G., Sayre P. H., Bahnson H. T., Radulovic S., Santos A. F., Brough H. A., Phippard D., Basting M., Feeney M., Turcanu V., Sever M. L., Lorenzo M. G., Plaut M., Lack G. and the LEAP Study Team: Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med, 378, 803-813 (2015)
86） Skripak J. M., Nash S. D., Rowley H., Brereton N. H., Oh S., Hamilton R. G., Matsui E. C., Burks A. W. and Wood R. A.: A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol, 122, 1154-1160 (2008)
87） Buchanan A. D., Green T. D., Jones S. M., Scurlock A. M., Christie L., Althage K. A., Steele P. H., Pons L., Helm R. M., Lee L. A. and Burks A. W.: Egg oral immunotherapy in nonanaphylaxtic children with egg allergy. J Allergy Clin Immunol, 119, 199-205 (2007)
88） 海老澤元宏，杉崎千鶴子，林典子，佐藤さくら，今井孝成：わが国における経口免疫（減感作）療法の実態．日本小児アレルギー学会誌，26，156-166 （2012）
89） Shek L. P. C., Bardina L., Castro R., Sampson H. A. and Beyer K.: Humoral and cellular responses to cow milk proteins in patients with milk-induced IgE-mediated non-IgE- mediated disorders. Allergy, 60, 912-919 (2005)
90） Ito K., Futamura M., Movérare R., Tanaka A., Kawabe T., Sakamoto T. and Borres M. P.: The usefulness of casein-specific IgE and IgG4 antibodies in cow’s milk allergic children. Clinical and Molecular Allergy, 10, 1 (2012)
91） Weiner H. L., du Cunha A. P., Quintana F., and Wu H.: Oral tolerance. Immunol Rev, 241, 241-251 (2011)
92） van Esch B. C. A. M., Schouten B., de Kivit S., Hofman G. A., Knippels L. M. J., Willemsen L. E. M. and Garssen J.: Oral tolerance induction by partially hydrolyzed whey protein in mice is associated with enhanced numbers of Foxp3+ regulatory T-cells in the mesenteric lymph nodes. Pediatr Allergy Immunol, 22, 820-826 (2011)
93） Meulenbroek L. A. P. M., van Esch B. C. A. M., Hofman G. A., Jager C. F. D. H., Nauta A. J., Willemsen L. E. M., Bruijnzeel-Koomen C. A. F. M., Garssen J., van Hoffen E. and Knippels L. M. J.: Oral treatment with b-lactoglobulin peptides prevents clinical symptoms in a mouse model for cow’s milk allergy. Pediatr Allergy Immunol, 24, 656- 664 (2013)
94） Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L. and Plevy S.: The incidence and management of infusion reaction to infliximab: a large center experience. Am J Gastroenterol, 98, 1315-1324 (2003)
95） Kolho K. L., Ruuska T. and Savilahti E.: Severe adverse reactions to infliximab theraphy are common in young children with inflammatory bowel disease. Acta Pædiatr, 96, 128-134 (2007)
96） Jönsson F., de Chaisemartin L., Granger V., Gouel-Chéron A., Gillis C. M., Zhu Q., Did F., Nicaise-Roland P., Ganneau C., Hurtado-Nedelec M., Paugam-Burtz C., Necib S., Keita-Meyer H., Dorze M. L., Cholley B., Langeron O., Jacob L., Plaud B., Fischler M., Sauvan C., Guinnepain M. T., Montravers P., Aubier M., Bay S., Neukirch C., Tubach F., Longrois D., Chollet-Martin S. and Bruhns P.: An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med, 11, eaat1479 (2019)
97） Jönssson F., Mancardi D. A., Zhao W., Kita Y., Iannascoli B., Khun H., van Rooijen N., Shimizu T., Schwartz L. B., Daëron M. and Bruhns P.: Human FcgRIIA induces anaphylactic and allergic reactions. Blood, 119, 2533-2544 (2012)
98） Jiménez-Saiz R.: Drug-induced IgG-neutrophil-mediated anaphylaxis in humas: Uncovered! Allergy, in press (2020)
論文の公開元へ
